While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

Immunology saw significant contributions from Beyfortus royalties, although Synagis declined year-over-year. Pipeline progress included the U.S. filing for Gamifant in secondary HLH and the ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Usually, MMWR includes three full studies. New data from Spain show Beyfortus, the antibody injection that protects babies from RSV, was highly protective there during the first year of its rollout.

Sobi's acquired immunology drugs (Astra's Synagis and Beyfortus, Novimmune's Gamifant, Apellis' Aspaveli) and hematology drugs (Dova's platelet drug Doptelet, ADC's blood cancer drug Zynlonta ...

The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centres for Disease Control and ...

The company's research-and-development spending increased 24% on-year in the last quarter in an attempt to bring further blockbusters such as its respiratory syncytial virus vaccine Beyfortus to ...

Lantus sales rose 63.4% to €439.0 million. SNY & AZN’s Beyfortus Drives Vaccine Sales Total vaccine sales increased 10.8% to €2.2 billion, driven by Beyfortus sales in Europe. Sales of flu ...

Total Revenue up 21% to $54,073m, driven by a 19% increase in Product Sales, continued growth of partnered medicines (Alliance Revenue) and the achievement of sales-based milestones (Collaboration ...

The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant ®, Vonjo and Zynlonta ®, and royalty on Sanofi's sales of Altuviiio ® and Beyfortus.